Idenix Pharma (IDIX) Initiates Concept Study for IDX320 in HCV Genotype-1 Infected Patients
Tweet Send to a Friend
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) today announced that it has initiated a 3-day proof-of-concept study of IDX320, a protease inhibitor ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
